Evidence map›Paper›PMID 29240263›Full record

ArticleEuropean journal of haematology2018

Cytochemical flow analysis of intracellular G6PD and aggregate analysis of mosaic G6PD expression.

Michael Kalnoky, Germana Bancone, Maria Kahn, Cindy S Chu, Nongnud Chowwiwat, Pornpimon Wilaisrisak, Sampa Pal, Nicole LaRue, Brandon Leader, Francois Nosten and 1 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in European journal of haematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Optimizing G6PD testing forWellcome open research · 2020
    Review
  8. Article
  9. Article
  10. Article
  11. Point-of-Care Testing for G6PD Deficiency: Opportunities for Screening.International journal of neonatal screening · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 4 countries.

Michael KalnokyDiagnostics Program, PATH, Seattle, WA, USA.
Germana BanconeShoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.
Maria KahnDiagnostics Program, PATH, Seattle, WA, USA.
Cindy S ChuShoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.
Nongnud ChowwiwatShoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.
Pornpimon WilaisrisakShoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.
Sampa PalDiagnostics Program, PATH, Seattle, WA, USA.
Nicole LaRueDiagnostics Program, PATH, Seattle, WA, USA.
Brandon LeaderDiagnostics Program, PATH, Seattle, WA, USA.
Francois NostenShoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.
Gonzalo J DomingoDiagnostics Program, PATH, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-1004-4395
Program for Appropriate Technology in Health · USMahidol University · TH

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundMedicines that exert oxidative pressure on red blood cells (RBC) can cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Due to X-chromosome inactivation, females heterozygous for G6PD with 1 allele encoding a G6PD-deficient protein and the other a normal protein produce 2 RBC populations each expressing exclusively 1 allele. The G6PD mosaic is not captured with routine G6PD tests.

methodsAn open-source software tool for G6PD cytofluorometric data interpretation is described. The tool interprets data in terms of % bright RBC, or cells with normal G6PD activity in specimens collected from 2 geographically and ethnically distinct populations, an African American cohort (USA) and a Karen and Burman ethnic cohort (Thailand) comprising 242 specimens including 89 heterozygous females.

resultsThe tool allowed comparison of data across 2 laboratories and both populations. Hemizygous normal or deficient males and homozygous normal or deficient females cluster at narrow % bright cells with mean values of 96%, or 6% (males) and 97%, or 2% (females), respectively. Heterozygous females show a distribution of 10-85% bright cells and a mean of 50%. The distributions are associated with the severity of the G6PD mutation.

conclusionsConsistent cytofluorometric G6PD analysis facilitates interlaboratory comparison of cellular G6PD profiles and contributes to understanding primaquine-associated hemolytic risk.

Indexed as

MosaicismMutationAllelesAntimalarialsAsian PeopleBlack or African AmericanCase-Control StudiesContraindications, DrugErythrocytesFemaleFlow CytometryGene Expression RegulationGlucosephosphate DehydrogenaseGlucosephosphate Dehydrogenase DeficiencyHemizygoteHeterozygoteAntimalarialsGlucosephosphate DehydrogenasePrimaquineG6PD deficiencyhemolytic anemialyonizationmalariaPlasmodium vivax

Identifiers

PMID29240263
PMCPMC5888147
OpenAlexW2774644390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.